—
C+
C+ The full Closelook — membership. Open the C+ overview

Pacific Biosciences of California (PACB) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Pacific Biosciences of California

PACB in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Pacific Biosciences designs and sells DNA sequencing systems built around its long-read SMRT technology, alongside the reagent kits and consumables that instruments consume with each run. Its machines, including the Revio, Vega and Sequel lines, read long strands of DNA to help researchers resolve complex genetic questions that shorter-read methods struggle with. Customers include academic and government labs, hospitals, pharmaceutical firms and agricultural researchers. It is based in Menlo Park, California.
Where it sits in the stack
PacBio sits outside Closelook's AI build-out index; within our wider universe it belongs to the life-sciences and genomic-tools sector, grouped with sequencing platform makers rather than chip, equipment or infrastructure names.
Who it is priced against
Closelook has not set a formal peer group for PacBio; the market usually places it alongside Illumina and Oxford Nanopore, the other sequencing platforms competing for long-read and short-read genomic volume.
Why Closelook tracks it
PacBio holds no seat in Closelook's index and carries no Closelook score; the diary has not yet quoted it in any edition.
What the diary watches
The diary watches whether adoption of its newer instruments turns into steady consumable and reagent sales, which would point to recurring sequencing volume rather than one-off machine purchases.

Pacific Biosciences of California (PACB) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for PACB, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against PACB on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Pacific Biosciences of California (PACB)?

Pacific Biosciences of California trades as PACB on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is PACB in a Closelook index?

Not currently — Pacific Biosciences of California is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does PACB trade against its moving averages?

Recovery attempt under the 200-day: Trades +2.3% vs the 50-day and -13.9% vs the 200-day average, 49.5% below the 52-week high and +29% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Pacific Biosciences of California do?

Pacific Biosciences designs and sells DNA sequencing systems built around its long-read SMRT technology, alongside the reagent kits and consumables that instruments consume with each run. Its machines, including the Revio, Vega and Sequel lines, read long strands of DNA to help researchers resolve complex genetic questions that shorter-read methods struggle with. Customers include academic and government labs, hospitals, pharmaceutical firms and agricultural researchers. Closelook has not set a formal peer group for PacBio; the market usually places it alongside Illumina and Oxford Nanopore, the other sequencing platforms competing for long-read and short-read genomic volume.

Where does Pacific Biosciences of California sit in the AI build-out?

PacBio sits outside Closelook's AI build-out index; within our wider universe it belongs to the life-sciences and genomic-tools sector, grouped with sequencing platform makers rather than chip, equipment or infrastructure names. PacBio holds no seat in Closelook's index and carries no Closelook score; the diary has not yet quoted it in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for PACB, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.